The U.S. Patent and Trademark Office (USPTO) recently issued a
new U.S. patent to
) BL-8040 (Patent No. 8,455,450).
The patent, which will expire in Nov 2029, will cover BL-8040
for using its composition for obtaining hematopoietic precursor
cells (e.g. stem cells) for use in bone marrow
This new patent boosts the existing patent portfolio of
BL-8040 which has 6 issued patents and 29 patents applications
for new indications across the globe.
BioLineRx' BL-8040 is in a phase II study for the treatment of
acute myeloid leukemia (AML). The multicenter, open-label, phase
II study is evaluating the safety and efficacy of repeated
escalating doses of BL-8040 in adults suffering from
Primary endpoints include safety and tolerability of BL-8040.
Secondary endpoints include the pharmacokinetic profile of the
candidate and an efficacy evaluation.
Last month, BiolineRx announced that BL-8040 showed positive
pre-clinical results for the treatment of thrombocytopenia
(reduced platelet production). The data was published in the
British Journal of Hematology.
The effect of repeated doses of BL-8040 on healthy as well as
chemotherapy-induced thrombocytopenic mice was evaluated in the
The number of megakaryocytes within the bone marrow improved
significantly with the repeated administration of BL-8040.
Megakaryocytes are the cells that produce platelets.
Moreover, BL-8040 increased the number of hematopoietic
progenitor cells in the bone marrow and blood. These cells
generate platelets as well as red and white blood cells. The
severity and duration of chemotherapy-induced thrombocytopenia
and cytopenia also declined significantly.
Thrombocytopenia is a frequent side effect of chemotherapy.
The candidate's ability to reduce thrombocytopenia makes it more
attractive for the use of blood cancer treatment.
We remind investors that in Sep 2012, the rights to BL-8040
were in-licensed by BioLineRx from Biokine Therapeutics Ltd.
Some of the candidates developed by BioLineRx include BL-5010
for the treatment of skin lesions, BL-7040 for the treatment of
inflammatory bowel disease (IBD) and BL-1021 for the treatment of
In Apr 2013, BiolineRx announced encouraging results from a
phase IIa study on BL-7040. Results from the study revealed that
BL-7040 was safe and effective for treating patients suffering
from ulcerative colitis which is a form of IBD.
BioLineRx carries a Zacks Rank #3 (Hold). Companies that
currently look well-positioned include
Gilead Sciences Inc.
) with a Zacks Rank #1 (Strong Buy), and
) with a Zacks Rank #2 (Buy).
ACTELION LTD (ALIOF): Get Free Report
BIOLINE RX LTD (BLRX): Get Free Report
GILEAD SCIENCES (GILD): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
To read this article on Zacks.com click here.